Levothyroxine sodium is an important medication used primarily for treating patients with hypothyroidism. Levothyroxine sodium tablets have been recalled many times since their 2024 introduction to the US market. These recalls resulted from the failure of lots to meet their
- TIROSINT-SOL (levothyroxine sodium) Oral Solution by IBSA Pharma. About this recall: IBSA Pharma is voluntarily recalling 27 lots of TIROSINT
Recall of TIROSINT SOL (levothyroxine sodium) Oral SolutionRecall of TIROSINT SOL (levothyroxine sodium) Oral Solution Recall of NP Thyroid TabletsRecall of
IPS Pharma is recalling specific batches of levothyroxine oral suspension from pharmacies and impacted patients due to the concentration of levothyroxine being
The last Recall Enforcement Report for Levothyroxine Sodium with NDC was initiated on as a Class II recall due to cgmp deviations: intermittent exposure to temperature excursion during storage. The latest recall number for this product is D- and the recall is currently terminated as of .
Examples include IBSA's Tirosint-Sol (levothyroxine sodium) recall in February 2024 as a result of subpotency. In addition, Spectrum recalled
The last Recall Enforcement Report for Levothyroxine Sodium with NDC was initiated on as a Class II recall due to subpotent and superpotent drug The latest recall
Drug recall: These Lots of Levothyroxine sodium Oral Solution recalled ; TIROSINT-SOL 25 mcg/mL 30 units carton-box, , , 02/
About this recall: IBSA Pharma is voluntarily recalling 27 lots of TIROSINT-SOL (levothyroxine sodium) Oral Solution to the consumer level.
Comments